

- 11:45 a.m.** **Abstract 47: Preliminary Findings on Cancer Incidence in HIV-Infected Persons from Six Countries in Central and South America and the Caribbean**
Daniel Masys, Vanderbilt University, USA
- 12:00 p.m.** **Abstract 86: Risk of Death Among Italian AIDS Cases With AIDS-Defining Cancers in the Post-HAART Era**
Diego Serraino, IRCCS Centro di Riferimento Oncologico, Italy
- 12:15 p.m.** **Lunch** (lunch on your own)
- 1:00 p.m.** **Poster Viewing** (Presenters stand by your poster)
- 2:00 p.m.–3:15 p.m.** **Session 3: Clinical Outcomes for AIDS-Related Haematologic Malignancies**
Chair: Alexandra Levine, M.D., City of Hope Medical Center
- 2:00 p.m.** **Abstract 41: Autologous Stem Cell Transplant (ASCT) for AIDS-Related Lymphoma (ARL)**
Amrita Krishnan, City of Hope National Medical Center, USA
- 2:15 p.m.** **Rituximab Plus Concurrent Infusional EPOCH Chemotherapy Is Highly Effective Without Excessive Toxicity in HIV-Associated, B-cell Non-Hodgkin's Lymphoma**
Joseph Sparano, M.D.
Montefiore-Einstein Cancer Center, Albert Einstein College of Medicine, New York City, USA
- 2:45 p.m.** **Abstract 26: Good Outcome of AIDS-Related Burkitt Lymphoma (BL) and Diffuse Large B-Cell Lymphoma (DLBCL) With Abbreviated Cycles of EPOCH-Rituximab**
Kieron Dunleavy, National Cancer Institute, USA
- 3:00 p.m.** **Abstract 59: Interim Results Of A Clinical Trial Using Oncolytic Virotherapy in Kaposi's Sarcoma-Associated Herpesvirus (KSHV) Associated-Multicentric Castleman's Disease (MCD)**
Robert Yarchoan, National Cancer Institute, USA
- 3:15 p.m.** **Break: Coffee and Poster Viewing**
- 3:30 p.m.–5:00 p.m.** **Session 4: International Studies**
Chair: Richard Ambinder, M.D., Ph.D., Johns Hopkins University
- 3:30 p.m.** **50th Anniversary of the Discovery of Burkitt's Lymphoma: Contributions to Epidemiology, Pathogenesis, and Treatment**
Ian Magrath, M.D.
International Network for Cancer Treatment and Research, Brussels, Belgium
- 4:00 p.m.** **Abstract 46: Kaposi's Sarcoma-Associated Immune Reconstitution Inflammatory Syndrome (KS-IRIS) in Africa: Initial Findings from a Prospective Evaluation**
Jeffrey Martin, University of California San Francisco, USA

- 4:15 p.m.** **Abstract 18: AIDS-Associated Kaposi Sarcoma in Uganda: Response to Treatment with Highly Active Antiretroviral Therapy and Chemotherapy**
Corey Casper, University of Washington, USA
- 4:30 p.m.** **Abstract 16: A Population-based Study of How Children Are Exposed to Saliva in Africa: Implications for KSHV Transmission**
Lisa Butler, University of California San Francisco, USA
- 4:45 p.m.** **Abstract 64: Implementation of a “See and Treat” Cervical Cancer Prevention Program Linked To HIV Care in Zambia**
Krista Pfaendler, Center for Infectious Disease Research in Zambia, Zambia
- 5:00 p.m.** **End of Day One**

OCTOBER 7

- 8:15 a.m.** **AIDS Cancer Specimen Resource (ACSR):
Role in Supporting HIV-Associated Cancer Research**
Michael McGrath, M.D., Ph.D., University of California, San Francisco, San Francisco, USA
- 8:30 a.m.–10:00 a.m.** **Session 5: KSHV Basic Biology**
Chair: *Scott Wong, Oregon Health & Science University*
- 8:30 a.m.** **KSHV-Encoded Micro-RNAs and Their Potential Role in Viral Biology
and Pathogenesis**
Rolf Renne, Ph.D.
University of Florida, Gainesville, USA
- 9:00 a.m.** **Abstract 58: Profiling of Cellular and Viral MicroRNAs in Kaposi Sarcoma
and Viral-Associated Lymphoma**
Dirk Dittmer, University of North Carolina at Chapel Hill, Chapel Hill, USA
- 9:15 a.m.** **Abstract 82: Profiling Viral and Host MicroRNA Expression in Cells
Infected With KSHV and EBV**
Denise Whitby, National Cancer Institute, USA
- 9:30 a.m.** **Abstract 31: Rapamycin Reduces Primary Effusion Lymphoma Progression
by Targeting VEGF Production and VEGF Responses**
Paola Gasperini, National Cancer Institute, USA
- 9:45 a.m.** **Abstract 22: Targeting the PI3K/Akt/MTOR Pathway
in KSHV-Associated Cancers**
Blossom Damania, University of North Carolina at Chapel Hill, Chapel Hill, USA
- 10:00 a.m.** **Break: Coffee and Poster Viewing**
- 10:30 a.m.–11:30 a.m.-** **Session 6: AIDS-Associated Lymphoma**
Chair: *Elliott Kieff, Harvard Medical School*
- 10:30 a.m.** **Abstract 23: High Resolution Profiling of DNA Copy Number and Gene
Expression Changes in AIDS-Related Lymphoma**
Karen Deffenbacher, University of Nebraska Medical Center, USA
- 10:45 a.m.** **Abstract 28: HIV Induces the Expression of Activation Induced Cytidine
Deaminase (AICDA) in B Cells through a Direct Interaction between Virion-
Associated CD40L and CD40**
Marta Epeldegui, University of California, Los Angeles, Los Angeles, USA
- 11:00 a.m.** **Abstract 83: Expression and Function of the Chemokine, CXCL13,
and its Receptor, CXCR5, in AIDS-Associated Non-Hodgkin's Lymphoma**
Daniel Widney, University of California, Los Angeles, Los Angeles, USA

- 11:15 a.m.** **Abstract 12: Incidence and Risk Factors and Survival and Prognosis of HIV-Associated Non-Hodgkin Lymphoma in the Era of Combined Antiretroviral Therapy: A European Multi-Cohort Study**
Julia Bohlius, University of Bern, Switzerland
- 11:30 a.m.** **Lunch** (lunch on your own)
- 12:00 p.m.** **Poster Viewing**
- 1:00 p.m.** **Session 7: New Viruses and Viral Mechanisms**
Chair: Doug Lowy, National Cancer Institute
- 1:00 p.m.** **New Human Polyomavirus Associated With Merkel Cell Carcinoma**
Yuan Chang, M.D.
University of Pittsburgh School of Medicine, Pittsburgh, USA
- 1:30 p.m.** **Abstract 11: Development and Application of Real Time PCR Assay for Detection and Quantification of Merkel Cell Virus (MCV) in Archived Formalin Fixed Paraffin Embedded Tissue Samples of Merkel Cell Carcinoma and Other Cancers**
Kishor Bhatia, National Cancer Institute, USA
- 1:45 p.m.** **Abstract 37: An Invasion Mechanism for Human Papillomavirus Related Cancers: HPV 16 E6 Degrades PTPN13 Allowing Enhanced MAP Kinase Signaling**
Andrew Hoover, University of Iowa, USA
- 2:00 p.m.** **Abstract 10: Generation of vFLIP Transgenic Mice: A Model to Study KSHV-Associated Lymphomagenesis**
Gianna Ballon, Weil Cornell Medical College, USA
- 2:15 p.m.** **HAART Rollout in AFRICA: Possible Impact on Cancer/New HTLV Viruses**
William Blattner, MD
Institute of Human Virology, University of Maryland School of Medicine, Baltimore, USA
- 2:45 p.m.** **Break: Coffee and Poster Viewing**
- 3:15 p.m.–4:30 p.m.** **Session 8: Non-AIDS Defining Cancers**
Chair: Richard Little, National Cancer Institute
- 3:15 p.m.** **Lung Cancer in the HIV Patient**
Malcolm Brock, M.D.
Johns Hopkins University School of Medicine, Baltimore, USA
- 3:45 p.m.** **Abstract 14: Immunodeficiency, HIV RNA Plasma Viral Load and Risk of AIDS-Defining and Non-AIDS-Defining Neoplasia, ANRS CO3 Aquitaine Cohort (1998–2006)**
Mathias Bruyand, INSERM, France

4:00 p.m.

**Abstract 21: Influence of HIV-Related Immunodeficiency
on the Risk of Hepatocellular Carcinoma**

Gary Clifford, International Agency for Research on Cancer, France

4:15 p.m.

**Abstract 44: Cisplatin and Radiation Therapy Induces an Immunologic
Clearance of HPV+ Head and Neck Cancer**

John Lee, University of Iowa

4:30 p.m.

Meeting Adjourned